Trojan, Jorg

Publishing since 1992 (Senior)

Has published 65 publications in 19 years

Number of publications published per year by Trojan, Jorg. (Source : PubMed)

Distribution of publications types for Trojan, Jorg. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.  Hepatology  2010;51;1  
•  Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zörnig M. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.  Hepatology  2009;50;4  
•  Casper M, Plotz G, Juengling B, Trojan J, Lammert F, Raedle J. Adenoma Development in a Patient with MUTYH-Associated Polyposis (MAP): New Insights into the Natural Course of Polyp Development.  Dig. Dis. Sci.  2009  
•  Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C, Endlicher E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.  Br. J. Cancer  2009;100;7  
•  Meyer C, Brieger A, Plotz G, Weber N, Passmann S, Dingermann T, Zeuzem S, Trojan J, Marschalek R. An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family.  Clin. Cancer Res.  2009;15;3  
•  Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.  Gastroenterology  2008;135;2  
•  Trojan J, Lubomierski N, Lehnert T, Engels K, Zeuzem S, Bechstein WO. Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.  Z Gastroenterol  2008;46;8  
•  Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.  Br. J. Cancer  2008;98;2  
•  Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, Herrmann T, Roth A, Chick J, Brock K, Albert D, Philip PA. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.  Invest New Drugs  2007;25;4  
•  Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H, Heinemann V. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.  Ann. Oncol.  2007;18;4  

[ See timeline ] [ See all publications ]